SHUKLA SANJAY (President and CEO) purchased 16.5% of their position (15K shares) of ATYR PHARMA INC on the open market
Open‑market purchase worth $17.6K — a significant purchase. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 12/12/2023ACC: 0001209191-23-058377
Officer· President and CEO
Since Feb 2019
+15K
Net shares
Net buyer
$17.6K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
15K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+3K
Price / share
$1.17
Trade value
$3.51K
% of position
3.3%
12/11/2023
91.17K→94.17K
Common Stock
Direct
Shares
+12K
Price / share
$1.18
Trade value
$14.14K
% of position
12.7%
12/12/2023
94.17K→106.17K
Total
Net shares
+15K
Net value
$17.65K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/11/2023 | P · Purchase | +3K | $1.17 | $3.51K | 3.3% | 91.17K | 94.17K |
| Common Stock Direct | 12/12/2023 | P · Purchase | +12K | $1.18 | $14.14K | 12.7% | 94.17K | 106.17K |
| Total | +15K | $17.65K | ||||||
Derivative Transactions0
No derivative transactions reported